Drug class
CD30-directed antibody–drug conjugate (brentuximab vedotin)
Mechanism of action
Brentuximab vedotin binds CD30 on target cells and is internalised. Lysosomal proteolysis releases monomethyl auristatin E (MMAE), which binds tubulin, disrupts microtubules, induces cell-cycle arrest and promotes apoptosis.
General use cases
- EMA-authorised indications include selected CD30-positive Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and cutaneous T-cell lymphoma settings; consult current product information for exact lines and combinations
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
